Table 1.
Patient demographics and rate of mCRC recommended molecular marker testing by patients’ characteristics
| Patient characteristic | Total, No. (%) |
KRAS, NRAS, or BRAF testinga |
MMR/MSI testing for de novo mCRC patients |
||||
|---|---|---|---|---|---|---|---|
| Not tested, No. (%) | Tested, No. (%) | P | Not tested, No. (%) | Tested, No. (%) | P | ||
| Total | 20 333 | 6798 (33.4) | 13 535 (66.6) | 5302 (45.22) | 6423 (54.78) | ||
| Median age at metastatic diagnosis, y (range) | 65 (18-85) | 69 (18-85) | 64 (18-85) | <.001 | 67 (23-85) | 61 (18-85) | <.001 |
| Age group, y | <.001 | <.001 | |||||
| 40 and younger | 788 (3.88) | 199 (25.25) | 589 (74.75) | 159 (28.55) | 398 (71.45) | ||
| 41-65 | 9422 (46.34) | 2562 (27.19) | 6860 (72.81) | 2325 (39.61) | 3544 (60.39) | ||
| 66-75 | 5488 (26.99) | 1798 (32.76) | 3690 (67.24) | 1454 (48.87) | 1521 (51.13) | ||
| Older than 75 | 4635 (22.80) | 2239 (48.31) | 2396 (51.69) | 1364 (58.69) | 960 (41.31) | ||
| Gender | .0487 | .28 | |||||
| Female | 11 201 (55.09) | 3117 (34.15) | 6011 (65.85) | 2375 (44.66) | 2943 (55.34) | ||
| Male | 9128 (44.89) | 3678 (32.84) | 7523 (67.16) | 2925 (45.67) | 3480 (54.33) | ||
| Stage at initial diagnosis | <.001 | ||||||
| I | 548 (2.70) | 195 (35.58) | 353 (64.42) | 0 | 0 | ||
| II | 2228 (10.96) | 814 (36.54) | 1414 (63.46) | 0 | 0 | ||
| III | 4902 (24.11) | 1549 (31.58) | 3354 (68.42) | 0 | 0 | ||
| IV | 11 725 (57.66) | 3777 (32.21) | 7948 (67.79) | 5302 | 6423 | ||
| Unknown | 930 (4.57) | — | — | — | — | ||
| Race | .24 | .42 | |||||
| African American | 2123 (10.44) | 656 (30.90) | 1467 (69.10) | 561 (44.24) | 707 (55.76) | ||
| Asian | 74 (0.36) | 172 (31.73) | 370 (68.27) | 120 (40.82) | 174 (59.18) | ||
| Hispanic or Latino | 542 (2.67) | 21 (30.90) | 53 (69.10) | 23 (50) | 23 (50) | ||
| White | 13 245 (65.14) | 4360 (32.92) | —8885 (67.08) | 3397 (45.09) | 4136 (54.91) | ||
| Other or unknownb | 4349 (21.39) | — | — | ||||
| ECOG performance status | <.001 | <.001 | |||||
| 0 | 6003 (29.52) | 1640 (27.32) | 4363 (72.68) | 1218 (36.38) | 2130 (63.62) | ||
| 1 | 5102 (25.09) | 1469 (28.79) | 3633 (71.21) | 1216 (41.09) | 1743 (58.91) | ||
| 2 | 1688 (8.30) | 651 (38.57) | 1037 (61.43) | 495 (48.43) | 527 (51.57) | ||
| 3 | 485 (2.39) | 243 (50.10) | 242 (49.90) | 170 (58.22) | 122 (41.78) | ||
| 4 | 50 (0.25) | 27 (54.00) | 23 (46.00 | 14 (48.28) | 15 (51.72) | ||
| Unknownc | 7005 (34.45) | — | — | — | — | ||
| Type of insurance | <.001 | <.001 | |||||
| Commercial | 7874 (38.53) | 2324 (29.67) | 5510 (70.33) | 1883 (39.75) | 2854 (60.25) | ||
| Commercial and Medicare | 3566 (17.54) | 1243 (34.86) | 2323 (65.14) | 890 (48.85) | 932 (51.15) | ||
| Medicare | 3238 (15.92) | 1262 (32.22) | 1976 (67.78) | 905 (50.53) | 886 (49.47) | ||
| Medicaid | 987 (4.85) | 318 (38.97) | 669 (61.03) | 288 (45.28) | 348 (54.72) | ||
| Medicare and Medicaid | 832 (4.09) | 291 (34.98) | 541 (65.02) | 205 (48.46) | 218 (51.54) | ||
| Other or unknown | 3876 (19.06) | 1360 (35.09) | 2516 (64.91) | 1231 (48.95) | 1285 (51.05) | ||
| Tumor location | .10 | .21 | |||||
| Left | 8702 (42.80) | 2804 (32.22) | 5898 (67.78) | 2025 (41.26) | 2883 (58.74) | ||
| Right | 4045 (19.89) | 1244 (30.75) | 2801 (69.25) | 1014 (42.80) | 1355 (57.20) | ||
| Unknown or unspecified | 7586 (35.93) | ||||||
| Practice type | N/Ac | N/A | — | N/A | N/A | — | |
| Academic | 1403 (6.90) | — | — | — | — | ||
| Community | 18 930 (93.10) | — | — | — | — | ||
a
Patients could have been tested for either BRAF, KRAS, or NRAS. “—” signifies no data; ECOG = Eastern Cooperative Oncology Group; mCRC = metastatic colorectal cancer; MMR = mismatch repair; MSI = microsatellite instability.
b
Patient without documented data in this category in the database.
c
Practice type information was only available for the full cohort for this analysis.